Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice

  1. Shun Kishimoto
  2. Jeffrey R Brender  Is a corresponding author
  3. Daniel R Crooks
  4. Shingo Matsumoto
  5. Tomohiro Seki
  6. Nobu Oshima
  7. Hellmut Merkle
  8. Penghui Lin
  9. Galen Reed
  10. Albert P Chen
  11. Jan Henrik Ardenkjaer-Larsen
  12. Jeeva Munasinghe
  13. Keita Saito
  14. Kazutoshi Yamamoto
  15. Peter L Choyke
  16. James Mitchell
  17. Andrew N Lane
  18. Teresa Fan
  19. W Marston Linehan
  20. Murali C Krishna  Is a corresponding author
  1. National Cancer Institute, National Institutes of Health, United States
  2. Hokkaido University, Japan
  3. National Institute of Neurological Disorders and Stroke, National Institutes of Health, United States
  4. University of Kentucky, United States
  5. GE Healthcare, Canada

Abstract

Metabolic differences among and within tumors can be an important determinant in cancer treatment outcome. However, methods for determining these differences non-invasively in vivo is lacking. Using pancreatic ductal adenocarcinoma as a model, we demonstrate that tumor xenografts with a similar genetic background can be distinguished by their differing rates of the metabolism of 13C labeled glucose tracers, which can be imaged without hyperpolarization using newly developed techniques for noise suppression. Using this method, cancer subtypes that appeared to have similar metabolic profiles based on steady state metabolic measurement can be distinguished from each other. The metabolic maps from 13C-glucose imaging localized lactate production and overall glucose metabolism to different regions of some tumors. Such tumor heterogeneity was not detectable in FDG-PET.

Data availability

Glucose imaging data and related files have been deposited to Dataverse at https://doi.org/10.7910/DVN/XU9XH9

Article and author information

Author details

  1. Shun Kishimoto

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  2. Jeffrey R Brender

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    For correspondence
    cherukum@mail.nih.gov
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7487-6169
  3. Daniel R Crooks

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  4. Shingo Matsumoto

    Graduate School of Information Science and Technology, Division of Bioengineering and Bioinformatics, Hokkaido University, Sapporo, Japan
    Competing interests
    No competing interests declared.
  5. Tomohiro Seki

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  6. Nobu Oshima

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  7. Hellmut Merkle

    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  8. Penghui Lin

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  9. Galen Reed

    Research Circle Technology, GE Healthcare, Toronto, Canada
    Competing interests
    Galen Reed, is affiliated with GE HealthCare. The author has no other competing interests to declare..
  10. Albert P Chen

    Research Circle Technology, GE Healthcare, Toronto, Canada
    Competing interests
    Albert P Chen, is affiliated with GE HealthCare. The author has no other competing interests to declare..
  11. Jan Henrik Ardenkjaer-Larsen

    Research Circle Technology, GE Healthcare, Toronto, Canada
    Competing interests
    Jan Henrik Ardenkjaer-Larsen, is affiliated with GE HealthCare. The author has no other competing interests to declare..
  12. Jeeva Munasinghe

    In Vivo NMR Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  13. Keita Saito

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  14. Kazutoshi Yamamoto

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  15. Peter L Choyke

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  16. James Mitchell

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  17. Andrew N Lane

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  18. Teresa Fan

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  19. W Marston Linehan

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  20. Murali C Krishna

    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    For correspondence
    murali@helix.nih.gov
    Competing interests
    No competing interests declared.

Funding

National Cancer Institute (1ZIASC006321-39)

  • James Mitchell

National Cancer Institute (Intramural Research Program)

  • Murali C Krishna

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The animal experiments were conducted according to a protocol approved by the Animal Research Advisory Committee of the NIH (RBB-159-2SA) in accordance with the National Institutes of Health Guidelines for Animal Research.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 3,512
    views
  • 427
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shun Kishimoto
  2. Jeffrey R Brender
  3. Daniel R Crooks
  4. Shingo Matsumoto
  5. Tomohiro Seki
  6. Nobu Oshima
  7. Hellmut Merkle
  8. Penghui Lin
  9. Galen Reed
  10. Albert P Chen
  11. Jan Henrik Ardenkjaer-Larsen
  12. Jeeva Munasinghe
  13. Keita Saito
  14. Kazutoshi Yamamoto
  15. Peter L Choyke
  16. James Mitchell
  17. Andrew N Lane
  18. Teresa Fan
  19. W Marston Linehan
  20. Murali C Krishna
(2019)
Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice
eLife 8:e46312.
https://doi.org/10.7554/eLife.46312

Share this article

https://doi.org/10.7554/eLife.46312

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Cancer Biology
    Yiwei Huang, Gujie Wu ... Cheng Zhan
    Research Article

    Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.